Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

33.21

+0.86

(+2.66%)

As of 03:09PM EST. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Inside Bar (Bullish)

View all chart patterns

Performance Outlook

Previous Close	32.35
Open	32.39
Bid	33.23 x 800
Ask	33.30 x 800
Day's Range	32.15 - 33.40
52 Week Range	31.79 - 56.40
Volume	753,901
Avg. Volume	803,720

Market Cap	4.676B
Beta (5Y Monthly)	1.25
PE Ratio (TTM)	11.94
EPS (TTM)	2.78
Earnings Date	Feb 21, 2022 - Feb 25, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	11.95

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

12% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for HALO

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Halozyme Therapeutics, Inc.
HALO: Lowering target price to $35.00HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
Rating
Fair Value
Economic Moat
6 days agoArgus Research

All

News

Press Releases

Research Reports

Insider Monkey
15 Best Stocks to Buy for 2022 According to Analysts
In this article, we discuss the 15 best stocks to buy for 2022 according to analysts. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks to Buy for 2022 According to Analysts. Even as inflation concerns overshadow an otherwise strong post-pandemic economic recovery towards the end […]
- Hedge Funds Are Coming Back To T. Rowe Price Group, Inc. (TROW)
  Insider Monkey
- Do Hedge Funds Love Madison Square Garden Sports Corp. (MSGS)?
  Insider Monkey
Zacks
Halozyme Therapeutics (HALO) Down 19.7% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR Newswire
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with Kyprolis® (carfilzomib) and dexamethasone (Kd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. This approval follows Janssen's regulatory submission to the FDA in February 2021.